POS0488 THE IMPACT OF ACHIEVING EARLY-SUSTAINED REMISSION USING BOOLEAN 2.0 CRITERIA ON PREVENTING FUNCTIONAL IMPAIRMENT IN RHEUMATOID ARTHRITIS
Authors: S. L. Lau, P. W. V. Chan, I. T. Cheng, C. C. Mok, C. Ho, T. T. Cheung, V. W. Lao, H. T. Pang, C. H. To, I. C. Yim, H. Y. Ng, K. Y. Kwok, K. L. Lee, K. Y. S. Ying, M. C. Wan, J. M. Lee, L. S. Tam
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Rheumatoid Arthritis (RA) is associated with functional impairment and disability. With the 2022 revision of the Boolean remission criteria, more patients can classified as achieving remission and the revised version also increases the agreement with index-based remission criteria without jeopardising predictive value for radiographic or functional outcomes. Whether achieving sustained Boolean 2.0 remission using a treat-to-target strategy aiming can prevent functional impairment in the long-term measured using the Health Assessment Questionnaires Disability Index (HAQ-DI) would need to be addressed. <h3>Objectives</h3> This retrospective study aims to explore the impact of sustained remission classified under the revised Boolean 2.0 criteria on HAQ-DI score. <h3>Methods</h3> The data was retrieved from the Clinical Rheumatology Systematic Treat-to-target (T2T) in Asia Leadership (CRYSTAL) registry. Early RA patients with symptoms onset less than 2 years were recruited between 2012-2018. All patients received a treat-to-target treatment strategy aiming at remission and had been followed for 5 years. Swollen joint count (SJC), tender joint count (TJC), Patient global assessment (PtGA), CRP levels, and HAQ-DI were recorded. Patients were classified into two groups: patients achieved Boolean 2.0 remission in both the first and second year (Early-Sustained Remission (ESR) Group), and patients who did not (Non-ESR group). <h3>Results</h3> The data of 236 patients were retrieved. 57 (24.2%) of them were classified as ESR group and 166 (70.3%) were in Non-ESR group (Table 1). The average HAQ-DI score was lower in the ESR group in the second, third, fourth and fifth year compared to the Non-ESR group with <i>p ≤</i> 0.001 [year 1: 0.097 ± 0.218 vs 0.403 ± 0.465; year 2: 0.143 ± 0.267 vs 0.421 ± 0.452; year 3: 0.212 ± 0.339 vs 0.476 ± 0.59; year 4: 0.232 ± 0.358 vs 0.457 ± 0.566] (Figure 1). <h3>Conclusion</h3> T2T aiming at achieving Boolean 2.0 remission in the first two years could be considered in clinical use for maintaining a lower functional impairment in the long term. <h3>References</h3> [1]Studenic P, Aletaha D, de Wit M, <i>et al</i>. American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. <i>Annals of the Rheumatic Diseases</i> 2023;82:74-80. [2]Chow E, Cheng I, Tam L, Hong Kong C. Impact of Achieving Early-sustained Remission on Preventing Long-term Functional Loss in Patients with Early Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Sze-Lok Lau: None declared, Pui Wing, Vivien CHAN: None declared, Isaac T. Cheng: None declared, Chi Chiu Mok Speakers bureau: GSK and Pfizer, Carmen Ho: None declared, Tommy T Cheung: None declared, Virginia W Lao: None declared, Hin Ting Pang: None declared, Chi Hung To: None declared, Isaac C Yim: None declared, Hoi Yan Ng: None declared, Kitty Yan Kwok: None declared, Ka Lai Lee: None declared, King Yee Shirley Ying: None declared, Man Choi Wan: None declared, Jolly M Lee: None declared, Lai-Shan Tam Consultant of: AbbVie, AstraZenaca, Boehringer Ingelheim, Eli Lilly, Janssen, Pfizer, and Sanofi, Grant/research support from: Amgen, Boehringer Ingelheim, GSK, Janssen, Novartis and Pfizer.